TrivarX Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

CEO

TrivarX heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kai Sun	Chief Operating Officer	1.3yrs	AU$173.73k	0.40% A$ 31.2k
Josh Purdy	Public Relations Director	no data	geen gegevens	geen gegevens
Archie Defillo	Chief Medical Officer	no data	geen gegevens	geen gegevens
Massimiliano Grassi	Head of Artificial Intelligence	4.8yrs	geen gegevens	geen gegevens
Anthony Keating	Executive Director	less than a year	geen gegevens	0.24% A$ 18.7k
Stephen Buckley	Company Secretary	1.6yrs	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van TRI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Keating	Executive Director	less than a year	geen gegevens	0.24% A$ 18.7k
Christopher Ntoumenopoulos	Independent Non-Executive Director	1.8yrs	AU$79.79k	1.33% A$ 103.1k
Peter Carlisle	Chairman of Growth & Advocacy Advisory Board	7.4yrs	AU$48.02k	geen gegevens
Patrick Kennedy	Member of Growth & Advocacy Advisory Board	5.3yrs	geen gegevens	geen gegevens
John Mathias	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Michael Phelps	Member of Growth & Advocacy Advisory Board	5.3yrs	geen gegevens	geen gegevens
David Trimboli	Independent Non-Executive Chairman	2.3yrs	AU$97.44k	geen gegevens
Elizabeth Lombardo	Member of Growth & Advocacy Advisory Board	3.2yrs	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van TRI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

TrivarX Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

Less than half of directors are independent

Less than half of directors are independent

Medibio Limited, Annual General Meeting, Nov 29, 2023

Medibio Limited, Annual General Meeting, Oct 06, 2023

Recent updates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

New major risk - Financial position

Less than half of directors are independent

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Less than half of directors are independent

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Less than half of directors are independent

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

CEO

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur